Drug-Eluting Stents and Antiplatelet Resistance

American Journal of Cardiology

Volumn 102, Issue 9 SUPPL., 2008, Pages 29J-37J

  Simon, Daniel I ^a   Jozic, Joseph ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CANGRELOR; CLOPIDOGREL; CYCLOOXYGENASE 1; IBUPROFEN; PADGEM PROTEIN; PRASUGREL; RIFAMPICIN; TICAGRELOR;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CAUSE OF DEATH; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; DRUG MEGADOSE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

EID: 54549084695     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.09.007     Document Type: Article

References (23)

1. Bhatt D.L. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol 43 (2004) 1127-1129
2. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., Sapp S.K., and Topol E.J. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
4. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
5. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
6. Wang J.C., Aucoin-Barry D., Manuelian D., Monbouquette R., Reisman M., Gray W., Block P.C., Block E.H., Ladenheim M., and Simon D.I. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 92 (2003) 1492-1494
7. Zimmermann N., Wenk A., Kim U., Kienzle P., Weber A.A., Gams E., Schrör K., and Hohlfeld T. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 108 (2003) 542-547
8. Snoep J.D., Hovens M.M.C., Eikenboom J.C.J., van der Bom J.G., and Huisman M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. Arch Intern Med 167 (2007) 1593-1599
9. Gurbel P.A., Bliden K.P., Hayes K.M., Yoho J.A., Herzog W.R., and Tantry U.S. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45 (2005) 1392-1396
10. Lau W.C., Gurbel P.A., Watkins P.B., Neer C.J., Hopp A.S., Carville D.G., Guyer K.E., Tait A.R., and Bates E.R. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109 (2004) 166-171
11. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., Novikov I., Pres H., Savion N., Varon D., and Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
12. Patti G., Colonna G., Paceri V., Pepe L.L., Montinaro A., and Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation 111 (2005) 2099-2106
13. Cuisset T., Frere C., Quilici J., Morange P.E., Nait-Saidi L., Carvajal J., Lehmann A., Lambert M., Bonnet J.L., and Alessi M.C. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48 (2006) 1339-1345
14. Barragan P., Bouvier J.L., Roquebert P.O., Macaluso G., Commeau P., Comet B., Lafont A., Camoin L., Walter U., and Eigenthaler M. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59 (2003) 295-302
15. Gurbel P.A., Bliden K.P., Samara W., Yoho J.A., Hayes K., Fissha M.Z., and Tantry U.S. Clopidogrel effect on platelet REactivity in patients with Stent Thrombosis: results of the CREST study. J Am Coll Cardiol 46 (2005) 1827-1832
16. Ajzenberg N., Aubry P., Huisse M.G., Cachier A., El Amara W., Feldman L.J., Himbert D., Baruch D., Guillin M.C., and Steg P.G. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol 45 (2005) 1753-1756
17. Wenaweser P., Dörffler-Melly J., Imboden K., Windecker S., Togni M., Meier B., Haeberli A., and Hess O.M. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 45 (2005) 1748-1752
18. Buonamici P., Marcucci R., Migliorini A., Gensini G.F., Santini A., Paniccia R., Moschi G., Gori A.M., Abbate R., and Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49 (2007) 2312-2317
19. Price M.J., Endemann S., Gollapudi R.R., Valencia R., Stinis C.T., Levisay J.P., Ernst A., Sawhney N.S., Schatz R.A., and Teirstein P.S. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29 (2008) 992-1000
20. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., Jacobs A.K., Kern M.J., King III S.B., Morrison D.A., O'Neil W.W., Schaff H.V., Whitlow P.L., et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) e166-e286
21. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., Zenni M.M., Guzman L.A., Bass T.A., and Costa M.A. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115 (2007) 708-716
22. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A., and Costa M.A. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516
23. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., Neumann F.J., Ardissino D., De Servi S., Murphy S.A., et al., TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015